阿立哌唑治疗阿尔茨海默病伴发精神行为症状对照研究

A control study of aripiprazole in the treatment of behavioral and psychological symptoms of Alzheimer’s disease

目的：探讨阿立哌唑治疗阿尔茨海默病伴发精神行为症状的疗效及安全性。方法将60例阿尔茨海默病伴发精神行为症状患者随机分为两组，研究组口服阿立哌唑治疗，对照组口服奋乃静治疗，观察6周。于治疗前后采用阳性与阴性症状量表评定疗效，副反应量表评定不良反应。结果治疗2周末起两组阳性与阴性症状量表总分及各因子分均较治疗前显著下降（ P＜0．05或0．01），治疗6周末研究组有效率93．3％，对照组为90．0％，两组有效率比较差异无显著性（χ^2＝0．22，P＞0．05）。研究组锥体外系反应（静坐不能、震颤、肌肉强直）发生率显著低于对照组（P＜0．01）。结论阿立哌唑治疗阿尔茨海默病伴发精神行为症状疗效显著，与奋乃静相当，但阿立哌唑治疗安全性更高，有利于提高患者的治疗依从性和生活质量。

Objective To explore the efficacy and safety of aripiprazole in the treatment of behavioral and psychological symptoms（BPS） of Alzheimer’s disease（AD） .Methods Sixty AD patients with BPS were randomly divided into two groups ,research group took orally aripiprazole and control group did perphenazine for 6 weeks .Clinical efficacies were assessed with the Positive and Negative Syndrome Scale （PANSS） and adverse reactions with the Treatment Emergent Symptom Scale（TESS） . Results Since the end of the 2nd week the total and each factor scores of both groups lowered more signifi‐cantly compared with pretreatment （P〈0 .05 or 0 .01）;at the end of the 6th week effective rate was respec‐tively 93 .3% in research and 90 .0% in control group ,which showed no significant group difference（χ^2 =0 .22 ,P〉 0 .05） .The incidences of extrapyramidal side effects （akathisia ,tremor and muscle rigidity ） were significantly lower in research than in control group （P〈0 .01） .Conclusion Aripiprazople has an evident effect equivalent to perphenazine in behavioral and psychological symptoms of Alzheimer’s disease , but the former has higher safety and is beneficial to the improvement of treatment compliance and quality of life.